Lung cancer is the leading cause of cancer deaths worldwide, mainly because it gets detected late. The discovery by the ...

AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

A recent analysis shows that additional invasive staging modalities lead to relevant changes in target volume in some ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

Approximately 40.5 percent of Americans will be diagnosed with cancer at some point in their life. It’s a diagnosis no ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

Chen, F. (2025) Advances in the Application of Deep Learning in Prognostic Models for Non-Small Cell Lung Cancer. Health, 17, ...

Economic Toxicity, Lung Cancer, Multi-Center Trial, Correlation Analysis Share and Cite: Mao, R.M. and Peng, L.Y. (2025) Multi-Center Investigation on the Level of Economic Toxicity in Patients with ...

Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in ...